Date: 2015-12-14
Type of information: Product acquisition
Compound: Prolia® (denosumab), XGEVA® (denosumab), Vectibix® (panitumumab)
Company: Amgen (USA - CA) GSK (UK)
Therapeutic area: Bone diseases - Cancer - Oncology
Type agreement: product acquisition
Action mechanism: monoclonal antibody. Denosumab is a fully human monoclonal antibody that binds to RANK Ligand, a protein essential for the formation, function and survival of osteoclasts (the cells that break down bone). Xgeva® prevents RANK Ligand from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction.
Vectibix® (panitumumab) is a fully human anti-EGFR antibody.
Disease: metastatic colorectal cancer, postmenopausal women with osteoporosis at high risk for fracture, increase of bone mass in men with osteoporosis at high risk for fracture, prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors, giant cell tumor of bone, hypercalcemia of malignancy refractory to bisphosphonate therapy
Details: * On December 14, 2015, Amgen announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) in 48 countries in Asia , South America , Europe , Australia and other regions throughout the world. The agreement involves key expansion markets for Amgen including Brazil , China , Colombia , Hong Kong , Israel , Singapore , South Korea , Taiwan and Thailand . GSK has held select regional rights to Prolia® and XGEVA® since 2009 and to Vectibix® since 2010 under license from Amgen. In 2014, GSK generated approximately $111 million in combined sales from these licenses. Amgen will make undisclosed milestone payments to GSK on signing and on the successful transition of the products back to Amgen . Amgen will book all product sales following this transition. Amgen anticipates this transaction to be accretive to adjusted earnings in 2017.
Financial terms:
Latest news:
